FEATURED SLIDESHOW
Who Is The Worst CEO?Mad Money needed new inductees for its
Wall of Shame, so we asked viewers for
nominations.
RECENT POSTS
- Lightning Round: CVS Caremark, Devon Energy, Tyson Foods and More
- Lightning Round OT: Ford, NewAlliance Bancshares and More
- Why You Should Speculate on Stocks
- Next Week’s Top IPO
- Cramer: 5 Earnings Reports to Watch Next Week
- More Americans Lighting Up? Buy This Stock
- What Happened to Cypress Semi?
- Lightning Round: Raytheon, Salesforce.com, Pepsi and More
- Lightning Round OT: Apache, Brocade, Allergan and More
- Cramer Goes One-on-One With Costco CEO

MAD MONEY FEATURES
Watch the Lightning Round whenever and wherever you want.
Grab this all-in-one application and get recaps of the show sent right to your desktop or blog.
Admit it: You've always wanted to hit the "They
know nothing!" button. Here’s your chance.
Check out Cramer on set, back to school, behind the scenes and more.
Buy Cramer books, bobbleheads and other Mad Money merchandise.
Pick up the phone! It's Cramer! New Mad Money sounds for your cell phone.
Mad Money's mobile. Get show highlights sent to your phone.
Wall Street doesn’t care about a company’s earnings last quarter, Cramer said Tuesday. The only thing that matters is the performance going forward. That’s why a consistent, stable firm like Bristol-Myers Squibb [BMY
Loading...
()
] can lose 4.3% in a single trading session, despite reporting solid numbers today. At the same time, Fortune Brands [FO
Loading...
()
] cut its dividend, but that stock finished the day higher by 3.9%.
What’s going on here? Wall Street sees signs of an economic recovery, so it is abandoning so-called safety stocks like Bristol-Myers for early-cycle plays like Fortune Brands. The focus is shifting from defense to growth because money managers expect a much better business environment six to nine months from now. That is what’s driving this market, and it’s the reason a seemingly undeserving stock like FO is rewarded with buying.
Cramer emphasized how important it is that viewers understand this trend. If investors wait for Fortune Brands to increase its dividend again or beat its earnings estimates, then they will pay $58 for the stock rather than $38. Sure, you could sit on BMY’s 6% dividend yield, but there’s no real capital appreciation to be had with that strategy.
The bottom line, Cramer said, is that come fall FO could be in much better shape, while Bristol-Myers will be about the same as it is now. That means Wall Street, addicted as it is to growth, is going all in on stocks like Fortune. Smart investors should do the same.
Questions for Cramer?
Questions, comments, suggestions for the Mad Money website?



